SAB Biotherapeutics, Inc.

NASDAQ:SABS

2.32 (USD) • At close September 3, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

202420232022202120202019
Operating Activities:
Net Income -34.105-42.194-17.145-17.14520.118-8.986
Depreciation & Amortization 4.7933.7453.2921.6540.5480.323
Deferred Income Tax 0000-0.0020
Stock Based Compensation 2.9422.4242.6742.3151.2950.371
Change In Working Capital -2.2992.32613.45513.455-11.954-0.923
Accounts Receivables -0.0555.55712.55912.559-17.751-2.563
Inventory 00000.4850
Accounts Payables 0.923-2.702-2.936-2.9365.2121.555
Other Working Capital -3.167-0.5293.8322.060.5850.084
Other Non Cash Items -5.6228.5791.4823.4800
Operating Cash Flow -34.292-25.1193.7593.75910.005-9.214
Investing Activities:
Investments In Property Plant And Equipment -0.337-0.197-10.944-10.944-12.732-0.609
Acquisitions Net 00.0440.07600.0090
Purchases Of Investments -37.44600000
Sales Maturities Of Investments 25.82100000
Other Investing Activites 00-0.076000
Investing Cash Flow -11.962-0.153-10.944-10.944-12.723-0.609
Financing Activities:
Debt Repayment -0.907-0.39-1.1851.544-0.9180
Common Stock Issued 0.0267.1647.6810.0079.90
Common Stock Repurchased 00-5.521000
Dividends Paid 000000
Other Financing Activities -0.28667.1640.07732.5699.93.682
Financing Cash Flow -1.17366.7731.05134.128.9823.682
Other Information:
Effect Of Forex Changes On Cash -0.2410.0180000
Net Change In Cash -47.66841.51926.93526.9356.264-6.142
Cash At End Of Period 8.89856.56639.54539.54512.616.346